Defense Health Agency (DHA) OMNIBUS IV is a $10 billion indefinite delivery, indefinite quantity (IDIQ) multiple-award contract that provides for a broad range of health-related research and development and support services that are of interest to the Department of Defense (DoD) and the Military Healthcare System (MHS), across the continental United States and OCONUS.

UCS, a wholly-owned subsidiary of Tria Federal, has been awarded an IDIQ contract for the following market segments:

• Market Segment 1: Research & Development
• Market Segment 2: R&D Support Services
• Market Segment 4: Translational Science Support and Services